Edgewise Therapeutics Announces Positive 2-Month Interim Results From The ARCH Open-Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)

As an early investor in Edgewise Therapeutics, CureDuchenne is pleased to share that their small molecule myosin inhibitor designed to protect injury-susceptible muscle fibers has shown positive results after 2 months treatment in Becker muscular dystrophy (BMD).  Individuals with BMD and taking daily doses of EDG-5506 showed significant decreases in key biomarkers of muscle damage, while their pedometer readings indicated increased activity levels.   You can learn more details about these promising results in Edgewise’s press release and via a webcast held Tues, June 21 at 9 am ET.